Veterinary Medicines

Alpramil 20 mg/200 mg tablets for dogs weighing at least 8 kg

Authorised
  • Milbemycin oxime
  • Praziquantel
Download as PDF

Product identification

Medicine name:
Alpramil 20 mg/200 mg tablets for dogs weighing at least 8 kg
Alpramil 20 mg/200 mg Tabletten
Alpramil 20 mg/200 mg Comprimés
Alpramil 20 mg/200 mg Tabletten
Active substance:
  • Milbemycin oxime
  • Praziquantel
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Milbemycin oxime
    20.00
    milligram(s)
    /
    1.00
    Tablet
  • Praziquantel
    200.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP54AB51
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Belgium
Package description:
  • Box with 10 OPA/Aluminium/PVC-Aluminium blisters each containing 1 tablet.
  • Box with 1 OPA/Aluminium/PVC-Aluminium blister containing 4 tablets.
  • Box with 25 OPA/Aluminium/PVC-Aluminium blisters each containing 4 tablets.
  • Box with 25 OPA/Aluminium/PVC-Aluminium blisters each containing 2 tablets.
  • Box with 25 OPA/Aluminium/PVC-Aluminium blisters each containing 1 tablet.
  • Box with 10 OPA/Aluminium/PVC-Aluminium blisters each containing 4 tablets.
  • Box with 10 OPA/Aluminium/PVC-Aluminium blisters each containing 2 tablets.
  • Box with 1 OPA/Aluminium/PVC-Aluminium blister containing 2 tablets.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Hybrid application (Article 13(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Alfasan Nederland B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Alfasan Nederland B.V.
  • Lelypharma B.V.
Responsible authority:
  • Federal Agency For Medicines And Health Products
Authorisation number:
  • BE-V600595
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0364/006
Concerned member states:
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Estonia
  • Finland
  • France
  • Germany
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 26/02/2024
Download
French (PDF)
Published on: 26/02/2024
Download
German (PDF)
Published on: 26/02/2024
Download

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 26/02/2024
Download
French (PDF)
Published on: 26/02/2024
Download
German (PDF)
Published on: 26/02/2024
Download

Combined File of all Documents

English (PDF)
Published on: 4/05/2022
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 26/02/2024
Download
French (PDF)
Published on: 26/02/2024
Download
German (PDF)
Published on: 26/02/2024
Download

NL_V_0364_004-006_DC Milpramax tablets for dogs-Final PuAR.pdf

English (PDF)
Published on: 29/02/2024
Download
How useful was this page?:
Average: 1 (5 votes)
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."